Inventor · disambiguated record
Jörg Wischhusen
Also filed as: WISCHHUSEN JOERG · WISCHHUSEN JORG · WISCHHUSEN JÖRG
10 granted patents·16 pending applications·26 citations·filing 2003–2025
87Inventor score
Files withUNIV WUERZBURG J MAXIMILIANS17CATALYM GMBH2JULIUS MAXIMILIANS UNIVERSITÄT WÜRZBURG2JULIUS MAXIMILLIANS UNIV WUERZBURG2BRUTTEL VALENTIN1
Top patents by PatentIndex Score
26 records- 0189US10781251B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)JULIUS MAXIMILLIANS UNIV WUERZBURG·Filed 2018·Granted Sep 22, 2020·6 cites·20 claims
- 0288US11760795B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Granted Sep 19, 2023·2 cites·32 claims
- 0388US11634482B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Granted Apr 25, 2023·2 cites·15 claims
- 0487US11891436B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)JULIUS MAXIMILLIANS UNIV WUERZBURG·Filed 2020·Granted Feb 6, 2024·2 cites·13 claims
- 0587US11262360B2GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Granted Mar 1, 2022·4 cites·10 claims
- 0687US10604565B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Mar 31, 2020·6 cites·18 claims
- 0783US11464856B2Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Granted Oct 11, 2022·3 cites·18 claims
- 0882US2023382987A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and usesthereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 0980US2024239882A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)UNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1077US2023408521A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1172US12473354B2GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Granted Nov 18, 2025·0 cites·11 claims
- 1271US2023416338A1Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulationUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1369US12497447B2Anti-GDF15 antibody and a dosage regimen for the treatment of cancerCATALYM GMBH·Filed 2025·Granted Dec 16, 2025·0 cites·17 claims
- 1468US2023093412A1Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 1565US2020386758A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Application pending·0 cites
- 1665US2025205323A1Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetesUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1763US2025222083A1Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody diseaseUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1863US2025205322A1Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmoUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1963US2025205321A1Mhc ib-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's diseaseUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 2063US2024043517A1Anti-gdf15 antibody and a dosage regimen for the treatment of cancerCATALYM GMBH·Filed 2023·Application pending·0 cites
- 2157US2019004047A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Application pending·0 cites
- 2257US2020157175A1Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulationBRUTTEL VALENTIN·Filed 2018·Application pending·0 cites
- 2355US2009312422A1Method of modulating cellular activity and agents useful for sameUNIV EBERHARD KARLS·Filed 2009·Application pending·0 cites
- 2453US7531575B2Method of modulating cellular activity and agents useful for sameEBERHARD KARLS UNI TUEBINGIN·Filed 2003·Granted May 12, 2009·1 cites·9 claims
- 2550US2015239968A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)JULIUS MAXIMILIANS UNIVERSITÄT WÜRZBURG·Filed 2013·Application pending·0 cites
- 2646US2017204174A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancerJULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jörg Wischhusen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →